BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

729 related articles for article (PubMed ID: 30648442)

  • 1. Technical considerations for circulating tumor DNA detection in oncology.
    Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
    Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 4. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enrichment and Analysis of ctDNA.
    Gilson P
    Recent Results Cancer Res; 2020; 215():181-211. PubMed ID: 31605230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
    Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
    Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
    Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
    Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing in liquid biopsy: cancer screening and early detection.
    Chen M; Zhao H
    Hum Genomics; 2019 Aug; 13(1):34. PubMed ID: 31370908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries.
    Alcaide M; Rushton C; Morin RD
    Methods Mol Biol; 2019; 1956():383-435. PubMed ID: 30779047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of cell-free DNA for molecular pathology.
    Stewart CM; Kothari PD; Mouliere F; Mair R; Somnay S; Benayed R; Zehir A; Weigelt B; Dawson SJ; Arcila ME; Berger MF; Tsui DW
    J Pathol; 2018 Apr; 244(5):616-627. PubMed ID: 29380875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection.
    Fiala C; Diamandis EP
    BMC Med; 2018 Oct; 16(1):166. PubMed ID: 30285732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
    Valpione S; Campana L
    Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.